JPRN-UMIN000001578未知未知
Tyrosine Kinase Inhibitor for the Treatment of Severe Pulmonary Arterial Hypertension - Tyrosine Kinase Inhibitor for Pulmonary Arterial Hypertension
Medical Education Center0 个研究点目标入组 10 人开始时间: 2008年12月16日最近更新:
适应症
试验速览
- 阶段
- 未知
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •patients who can not express subjective symptoms, can not be evaluated through objective improvement, have the decreased number of platelet (less than 30000), have critical anemia (Hb<7.0), have critical liver cirrhosis, are during pregnancy or during lactation, or have critical left heart disease
研究者
相似试验
进行中（未招募）
不适用
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL)MedDRA version: 14.1Level: LLTClassification code 10000844Term: Acute lymphoblastic leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10034877Term: Philadelphia chromosome positiveSystem Organ Class: 10022891 - InvestigationsEUCTR2010-022946-25-Outside-EU/EEAChildren's Oncology Group195
进行中（未招募）
1 期
A muulticenter study to evaluate drug response for the treatment of a white blood cell cancer in early chronic phaseEUCTR2011-002787-25-ITG.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO120
进行中（未招募）
不适用
A multicenter study to evaluate drug response for the treatment of a white blood cell cancer in early chronic phase.EUCTR2007-000597-22-ITG.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
尚未招募
不适用
Multikinase Inhibitor (Tyrosine and Serine/Threonine Kinase Inhibitor) for the Treatment of Severe Pulmonary Arterial Hypertensiopulmonary arterial hypertensionJPRN-UMIN000001709Medical Education Center, School of Medicine, Keio University10
已完成
不适用
Discontinuation of tyrosine kinase inhibitor treatment in patients who have obtained complete molecular response after treatment with tyrosine kinase inhibitors for chronic myeloid leukemiaChronic myeloid leukemiaJPRN-UMIN000004798Keio University School of Medicine, Division of Hematology70